They made the suggestion to MND, not the other way around.
I hardly think they deliberately dragged out the trials. Elanco walking out on them a couple of months after the end of the first phase 2 dog trial in 2020 threw a massive spanner into PAAs plans. It was clear that they were completely caught by surprise and had to put on a brave face on it all. They thought they;d be working out the remaining tolerability issues and the optimum dose level (remember, they had just discovered mpl's bi-phasal quality in that trial) with the help of Elanco. On top of that you had the massive disruption to everything that year and the next by the biggest pandemic in a century. What has been achieved howvever in that time, despite their minimal budget and all the problems they had to be worked through, deserves to be recognised.
- Forums
- ASX - By Stock
- PAA
- Ann: MND Trial Successfully Completes First Patient Cohort
Ann: MND Trial Successfully Completes First Patient Cohort, page-123
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
22.5¢ |
Change
0.010(4.65%) |
Mkt cap ! $109.4M |
Open | High | Low | Value | Volume |
21.5¢ | 22.5¢ | 21.5¢ | $347.6K | 1.569M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 38000 | 22.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.0¢ | 297083 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 38000 | 0.225 |
8 | 258779 | 0.220 |
11 | 874363 | 0.215 |
5 | 120849 | 0.210 |
3 | 148485 | 0.205 |
Price($) | Vol. | No. |
---|---|---|
0.230 | 297083 | 9 |
0.235 | 170709 | 3 |
0.240 | 214527 | 3 |
0.250 | 333860 | 7 |
0.260 | 410162 | 3 |
Last trade - 11.56am 14/10/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |